Summary
Glioblastoma (GBM) is the most aggressive form of glioma, with poor prognosis exhibited by most patients, and a median survival time of less than two years. To examine survival-associated patterns, we assembled a cohort of 87 GBM patients whose survival ranges from less than 3 months and up to 10 years, most of which are not bearing isocitrate-dehyderogenase (IDH)-1 mutation and did not undergo prior treatment. We integrated high-resolution mass-spectrometry proteomics and RNA-sequencing to examine the yet unresolved proteomic contribution to poor patient outcome, and compared it to the more established transcriptomic contribution and to published single-cell RNA-sequencing data. Discovering both layer-specific and shared processes, we found that immune, metabolic and developmental processes distinguish short and long survival periods. Additionally, we observed a significant discrepancy in tumor classification between expression layers. Overall, our integrative findings establish proteomic heterogeneity in GBM as a gateway to understanding poor patient survival.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The Geiger laboratory has received partial Funding from the European Research Council (ERC) starting grant [639534], the Israel Science Foundation (grant 748/16) and the Gail White and Anne and William Cohen Multidisciplinary Brain Cancer Research Program. The Satchi-Fainaro laboratory has received partial funding from the European Research Council (ERC) Consolidator Grant Agreement no. [617445]-PolyDorm and ERC Advanced Grant Agreement no. [835227] - 3DBrainStrom; The Israel Science Foundation (Grant nos. 918/14 and 1969/18); Israel Cancer Research Fund; Nancy and Peter Brown friends of The Israel Cancer Association (ICA) USA, in memory of Kenny and Michael Adler (20150909); and from the Morris Kahn Foundation. E.Y. is a fellow at the Gail White and Anne and William Cohen Multidisciplinary Brain Cancer Research program. P.O. thanks the Naomi Foundation for the Global Research and Training Fellowship in Medical and Life Sciences.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD018024. The RNA-seq data have been deposited in NCBI's Gene Expression Omnibus (Edgar et al., 2002) and are accessible through GEO Series accession number GSE149009 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE149009).
